Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content. Erasca’s pitch is straightforward: The U.S.-based biotech says it went to China and found a more potent, better-tolerated pan-RAS inhibitor than Revolution Medicines’ Rasonque. To date, Erasca has backed up its claim with scant data from an early-stage study disseminated via press releases. The story might be true, it might not be, but for now that’s less important to investors than Erasca’s $5 billion market value, which is a fraction of the $35 billion carried by Revolution Medicines. The valuation disparity makes sense given Revolution’s lead, but it also stokes speculation that Erasca could be an attractive takeover target. On Friday, the company is presenting another slug of data on its drug, called ERAS-0015, at the EORTC-NCI-AACR “Triple” meeting in Barcelona. Erasca knows what it’s presenting already, obviously, so without breaking the meeting’s embargo policy, CEO Jonathan Lim has been signaling to investors at investment banking conferences that a “4-handle” — Wall Street lingo for 40%-ish — overall response rate from ERAS-0015 in second line-plus pancreatic cancer would be “meaningfully different” from Rasonque. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe
STAT+: In cancer drug development, the spotlight shifts onto Erasca’s KRAS-targeted treatment
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.